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The cardiorenal syndrome includes the widely known relationship between kidney function and cardiovascular disease. A large
number of patients have various degrees of heart and kidney dysfunction worldwide, both in developed and developing countries.
Disordersaﬀectingoneofthemmostlyinvolvetheother.Suchinteractionsrepresentthepathogenesisforaclinicalconditioncalled
cardiorenal syndrome. Renal and cardiovascular disease shares similar etiologic risk factors. The majority of vascular events are
caused by accelerated atherosclerosis. Moreover, cardiovascular events rarely occur in patients without underlying disease; rather,
they typically take place as the ﬁnal stage of a pathophysiological process that results in progressive vascular damage, including
vital organ damage, speciﬁcally the kidney and the heart if these factors are uncontrolled. Chronic kidney disease is a novel risk
factor included at this stage that accelerates both vascular and cardiac damage.
1.Introduction
The interaction between renal and cardiac function is
very important for regulatory functions and hemodynamic
control. The kidney plays the central role for body ﬂuid
volume homeostasis, electrolyte balance, and blood pressure
regulation [1]. The relationship between heart and kidney
occurs at multiple levels, including the rennin-angiotensin-
aldosterone system (RAAS), the sympathetic nervous system
(SNS),natriureticpeptides,endothelin,andantidiuretichor-
mones [2]. Therefore, understanding these two important
systems is crucial to improve the management of patients
withcardiorenaldisease. An aging population and increasing
incidence of hypertension, type 2 diabetes mellitus, obesity,
and other cardiovascular (CV) risk factors are associated
with an increasing incidence of cardiorenal disorders. Hence,
it is not surprising that the prevalence of heart failure
and chronic kidney disease (CKD) continues to increase.
Furthermore, it has been shown that even mild-to-moderate
deterioration of kidney function correlates with higher mor-
bidity and mortality in patients with heart failure and acute
coronary syndrome [3]. The strong relationship between
CKDandacceleratedCVdiseasemorbidityandmortalityhas
beenshowninseveralepidemiologicdataandclinicalstudies
[4]. Moreover, whereas death rates from coronary artery
diseasehavefallenby35%inthelastdecadeasaconsequence
of control of CV risk factors and optimal therapeutic
management, patients with CKD have not accomplished that
trend during that period. A signiﬁcant number of patients
with CKD die of CV complications before they progress to
end-stage renal disease (ESRD), and renal dysfunction in
patientswithprimarycardiacdiseaseportendsasigniﬁcantly
enhanced risk of morbidity and mortality from CVD [5].
Thus, with the aging of the population and control of CV
risk factors, especially arterial hypertension, understanding
the mechanisms of renal dysfunction as a pathogenic factor
for cardiovascular (CV) disease is imperative.
2.Pathophysiological Mechanisms Underlying
the CardiorenalDisease
CVDs are a leading cause of death and serious morbidity or
disabilitiesworldwide,andCVeventsrarelyoccurinpatients
without underlying disease; rather, they typically take place















Figure 1: Graphic representation of the cardiorenal continuum.
in progressive vascular damage. This stage is called the
cardiorenal continuum [6]. Figure 1 displays an overview of
the cardiorenal continuum, illustrating a simpliﬁed version
of the sequential occurrence of the atherosclerotic process
from the ﬁrst stage, in which CVD risk factors are detected
and can be prevented if the conditions are appropri-
ately controlled by implementing the optimal therapeutic
approaches. A consensus conference has recently presented
a classiﬁcation of cardiorenal disease, including a division of
ﬁve subtypes of cardiorenal syndromes, according to their
pathophysiological mechanisms [7].
Renal and CV diseases share the same etiopathogenic
risk factors, including hypertension, dyslipidemia, glucose
metabolism disturbances, cigarette smoking, obesity, and
physical inactivity. If these factors are controlled, then
atherosclerotic process evolution and further target-organ
damage (TOD) or CV events can be prevented. Therefore,
prevention can be carried out not just at the ﬁrst stage
but along the whole continuum. As the cardiorenal process
advances, atherosclerotic vascular damage progresses, and
subclinical organ damage can be detected. This is an
intermediate stage in the continuum of vascular disease
and a determinant of overall CVD risk. CKD is included
at this stage, and a number of conditions associated with
renal-function decline, such as anemia, secondary hyper-
parathyroidism, or accumulation of atherogenic substances,
become new CVD risk factors and accelerate vascular
disease. Therapeutic approaches at this point can regress CV
damage, as shown in the Losartan Intervention for Endpoint
Reduction in Hypertension (LIFE) study, in which reduced
urinary albumin/creatinine ratio (UACR) and regression of
left ventricular hypertrophy (LVH) were associated with
lower incidence of CV events. Therefore, strict objectives
regarding CVD risk factors must be set up. A large body
of evidence is now available concerning the crucial role of
TOD in determining the CVD risk of individuals with and
without hypertension. If regression of CV damage is not
achieved, the process advances to the development of CV
events and progression of CKD to overt nephropathy and
CVD. Although prevention strategies must be present along
thecontinuum,interventionsatthispointshouldonlyretard
the occurrence of CV and renal events [8]. This last stage
represents the situation of further progression of vascular
disease, leading to the appearance of symptomatic TOD
(myocardial infarction, angina, stroke, transient ischemic
attack, advanced chronic renal failure, and peripheral artery
disease), which eventually will lead to end-stage renal disease
(ESRD) or death. At this stage, the best we can do is to retard
the likelihood of such events.
3.CardiovascularDiseaseAssociatedwith
Renal Disease
Underlying the cardiorenal continuum is the pathophysio-
logical continuum, which describes the progressive processes
at molecular and cellular levels that manifest as clinical
disease. A vast amount of research over the last two decades
has provided considerably more knowledge regarding the
therapeutic interventions that are able to intervene along the
continuum.
Therefore, as CVD risk factors can be evaluated, the
process begins. At this ﬁrst stage of cardiorenal disease,
preventative approaches are the most relevant strategies
to disrupt disease progression [9]. In this sense, some
data have demonstrated that high-risk patients without
evidence of renal damage may beneﬁt from early therapeutic
intervention. The multicenter, double-blind, randomized
Bergamo Nephrologic Diabetes Complications Trial (BENE-
DICT) assessed whether pharmacological intervention could
prevent microalbuminuria in high-risk patients with no
evidence of organ damage. The main results showed that
intervention decreased the incidence of microalbuminuria
[10]. Evidence from other ongoing trials will shed light on
this issue, as will the Randomised Olmesartan and Dia-
betes Microalbuminuria Prevention (ROADMAP) study—
a placebo-controlled, multicenter, double-blind, parallel
group study investigating the eﬀect of the angiotensin recep-
tor blocker (ARB) olmesartan medoxomil on the incidence
of microalbuminuria in hypertensive people with type 2
diabetes and an objective of blood pressure <130/80mmHg.
In addition, ROADMAP will also analyze eﬀects of olme-
sartan medoxomil on retinopathy and other microvascular
circulations [11]. The results of the Diabetic Retinopathy
Candesartan Trials (DIRECTs) are designed to examine
primary(incidence)andsecondary(progression)prevention
of diabetic retinopathy when blocking angiotensin II type
1 receptors with the ARB candesartan in patients with
normoalbuminuric, normotensive type 1 diabetes, and sec-
ondary prevention only in patients with normoalbuminuric,
normotensive, or treated hypertensive type 2 diabetes. This
trial series will also support prevention strategies to block
advancement of the atherosclerotic process that leads to
development of CV damage [12].
Optimal management in people with several risk factors
is crucial, especially when hypertension is associated with
other conditions. Awareness that several antihypertensive
agents may exert undesirable metabolic eﬀects has antihy-
pertensive treatment trials to investigate the incidence ofInternational Journal of Nephrology 3
new-onset diabetes. Almost all such trials with new-onset
diabetes as an endpoint have shown a signiﬁcantly greater
incidence in patients treated with diuretics and/or beta-
blockers compared with angiotensin-converting enzyme
inhibitors (ACEIs), ARBs, or calcium antagonists [13–16].
Angiotensin receptor antagonists [17]a n dA C E I s[ 13]h a v e
been shown to be associated with signiﬁcantly fewer new
diabetes cases than were calcium antagonists. The Ongoing
TelmisartanAloneandinCombinationwithRamiprilGlobal
Endpoint Trial (ONTARGET) is comparing telmisartan,
ramipril, and their combination for preventing CVD mor-
bidity and mortality in high-risk patients [18]. Telmisartan
wastheARBselectedfortheONTARGETbecauseitprovides
sustained antihypertensive activity over the 24h between
doses [19]. The comparator, the ACEI ramipril, was selected
because in the Heart Outcomes Prevention Evaluation
(HOPE) trial, ramipril was proved to reduce the incidence
of CV events in a similar patient population [20]. Patients
enrolled in ONTARGET have vascular disease (coronary
artery disease, peripheral arterial occlusive disease, stroke)
or diabetes with TOD. The primary outcome is a composite
endpoint of CVD, death, stroke, acute myocardial infarction,
and hospitalization for congestive heart failure. A variety of
renal endpoints have also been included. The Telmisartan
Randomized Assessment Study in ACE-I-Intolerant Subjects
with CV Disease (TRANSCEND) is a parallel study within
the ONTARGET that is comparing the CV protective eﬀect
of telmisartan with placebo in patients intolerant of ACEIs
[18]. The ﬁrst results of this trial have been published and
emphasize that the telmisartan was equivalent to ramipril
in treating patients with vascular disease or high-risk
diabetes and was better tolerated [21]. The combination
of these two drugs was associated with more adverse
events without an increased beneﬁt. More evidence about
prevention along the cardiorenal continuum is expected
from this trial, including more than 150,000 patient-years
of data. The Trial of Preventing Hypertension (TROPHY)
hypothesized that early treatment with candesartan might
prevent or delay hypertension onset. The main results
showed that candesartan was better in preventing devel-
opment of hypertension versus placebo [22]. The Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT) evaluated
the beneﬁts associated speciﬁcally with the use of statins
among patients with hypertension [23]. Atorvastatin, which
was added to the treatment therapy in more than 10,000
patients with hypertension and additional CVD risk factors
and a serum total cholesterol <6.5mmol/L, reduced serum
total cholesterol by 19.9% compared with placebo. This was
accompanied by substantial beneﬁts both with regard to
total CV and renal events (36% reduction) and stroke (27%
reduction). The Avoiding Cardiovascular Events through
Combination Therapy in Patients Living with Systolic
Hypertension(ACCOMPLISH)trialwasrecentlyterminated
prematurely because the predeﬁned eﬃcacy outcome was
achievedandaninterimanalysisreported.Thetrialrecruited
more than 11,400 patients who received either amlodipine
in combination with benazepril or hydrochlorothiazide in
combinationwithbenazepril.Aprimarycompositeendpoint
of CVD morbidity or mortality was deﬁned as death from
CV causes, fatal or nonfatal myocardial infarction or fatal or
nonfatal stroke, revascularization, or unstable angina requir-
ing hospitalization. Treatment with amlodipine/benazepril
signiﬁcantly reduced CVD morbidity and mortality com-
pared with hydrochlorothiazide/benazepril (relative risk
(RR) 0.80; 95% conﬁdence interval (CI) 0.71–0.90) [24].
Mechanical and chemical damages resulting from these
interrelated CVD risk factors promote general progression
of vascular damage that begins with endothelial dysfunction
and atherosclerosis. This leads to end-organ damage, such as
LVH,subclinicalatheroscleroticvasculardamage,andkidney
injury that can be detected by microalbuminuria and renal
function derangement (estimated glomerular ﬁltration rate
(eGFR) <60mL/min/1.73m2 or a slight increase in serum
creatinine). At this second stage, vascular damage processes
may be regressed, and inhibition of the rennin-angiotensin
system (RAS) has been shown to be the most eﬃcient
pharmacological intervention along with strict control of
CVD risk factors.
International guidelines devoted to arterial hyperten-
sion recognize microalbuminuria, elevated serum creatinine
values, and reduced eGFR as major CVD risk factors that
contribute to increased risk aﬀorded by other coexisting
factors [25–27]. The diagnosis of hypertension-induced
renal damage in a hypertensive patient is usually based on
reduced renal function and/or elevated urinary excretion of
albumin. Renal function decline is classiﬁed in accordance
with eGFR calculated by the abbreviated Modiﬁcation of
Diet in Renal Disease (MDRD) formula that assesses age,
gender, race, and serum creatinine [28]. Values of eGFR
<60mL/min/1.73m2 indicate CKD stage 3, whereas values
<30 and 15 mL/min/1.73m2 indicate CKD stages 4 and
5, respectively [29]. The Cockcroft-Gault formula estimates
creatinine clearance (CrCl) and is based on age, gender,
body weight, and serum creatinine [30]. This formula is
applicable in the range >60mL/min, but it overestimates
CrCl in CKD stages 3–5 [31]. Both procedures help to
detect mildly impaired renal function in the face of serum
creatinine values that are still in the normal range.
Reduction in GFR and increase in CVD risk may also
be inferred from increased serum levels of cystatin C [32].
Whereas elevated serum creatinine concentration or low
eGFR (or CrCl) points to reduced rate of plasma ﬁltered at
the glomerular level, increased urinary albumin or protein
excretion points to derangement in the glomerular ﬁltration
barrier, which allows increased albumin passage. Microal-
buminuria has been shown to predict the development of
overt diabetic nephropathy in those with either type 1 or
type 2 diabetes [33]. However, only about 40% of those
with type 2 diabetes will develop microalbuminuria, and,
of those, approximately 50% will develop microalbuminuria
in the following 10 years [34]. In contrast, in both diabetic
and nondiabetic hypertensive patients, microalbuminuria,
even below the threshold values currently considered [35],
has been shown to predict CV events. Several studies
report a continuous relationship between CVD—as well as
non-CVD—mortality and urinary protein/creatinine ratios
>3.9mg/g in men and 7.5mg/g in women [36]. Thus, the
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falsely suggests a minor injury as well) and should, in theory,
be replaced by the term “low-grade albuminuria” [37].
Microalbuminuria can be determined in spot urine samples
(24h or night-time urine samples are discouraged due to
inaccuracy of urinary sampling) by indexing the urinary
albumin concentration to the urinary creatinine concen-
tration. Initial evidence concluding that microalbuminuria
increases CVD risk came from observations involving high-
riskpatients[38].DatafromtheHOPEstudy[39]c onﬁrmed
the predictive value of microalbuminuria, which attained
a predictive capacity similar to that of previous coronary
artery disease and was equal for patients with and without
accompanying diabetes. The relevance of urinary albumin
excretion (UAE) as a CVD risk factor in patients with hyper-
tension without diabetes and in the general population has
also been demonstrated [40]. Some of these studies indicate
that the relationship between urinary albumin and CVD risk
is a continuum that starts below the established cutoﬀ point
indicated earlier. Deﬁnitely, both UAE and reduced GFR are
independently associated with increased CVD risk, which is
particularly elevated when both alterations coexist [41]. In
fact, the prevalence of albuminuria, either micro or macro,
increases as eGFR falls <60mL/min/1.73m2 [42].
Patients developing ESRD are a minority in the group
developing diﬀerent forms of CKD. They could be con-
sidered survivors because CVD accounts for the majority
of deaths of patients with CKD before the development
of ESRD [43]. In turn, advanced CVD facilitates the
development of CKD, and so the relationship between CKD
and CVD becomes a vicious circle. That CKD and CVD
are so closely related has resulted in increased interest
in investigating the evolution of renal function in trials
involving patients with hypertension, as well as those with
heart failure and postmyocardial infarction. This interest
is fully justiﬁed, as, in all these situations, renal function
alterations are predictive for the development of CV events
or death.
Even from the early stages, CKD adds to CVD risk in
any patient with hypertension and in any patient presenting
with established forms of CVD [44]. Reduction of CV events
in the CKD population requires the implementation of
eﬀective integral therapeutic interventions that protect both
the kidney and the CV system. These interventions have to
be implemented in the very initial stages of CKD, and strict
blood pressure control is imperative in any patient with an
elevated global CVD risk and high blood pressure. In the
absence of other CVD risk factors, elevated blood pressure
levels are required in order to consider patients as having
high-added CVD risks. In contrast, only high-normal blood
pressure levels or even lower values are required for the
same evaluation when patients present with three or more
associated CVD risk factors, TOD, diabetes, or associated
clinical conditions. Accordingly, patients with hypertension
and a high-added level of CVD risk can be found in any of
the three stages of the CV and renal disease continuum. As
soon as renal function exhibits minor derangements, CVD
risk continues to increase until ESRD develops.
As renal function declines, TOD appears and CKD adds
several clinical characteristics that raise the possibility of a
CV eventas atheroscleroticdisease progresses. CKD-induced
anemia and secondary hyperparathyroidism globally worsen
outcomes in patients with and without myocardiopathies,
and correction of these conditions is crucial to reduce
absolute CVD risk [45, 46]. Among patients who referred
to the authors’ hypertension unit, 7.6% had a decreased
renal function according to serum creatinine levels, and 25%
had a decreased CrCl [47]. Community-based longitudinal
studies demonstrated that CKD is an independent risk factor
for the composite study outcome, including myocardial
infarction, fatal congestive heart failure, stroke, and death
[48]. In patients with essential hypertension and normal
renalfunction(deﬁnedaseGFR>90mL/min/1.73m2),those
who developed CKD during 13 years of followup had a CV
event rate 2.5 times higher than did those with preserved
renal function [49]. As widely evidenced in the hypertensive
population, the higher the CVD risk, the higher the CKD
prevalence [50].
Evidence for the relationship between renal dysfunction
and adverse CV events was initially documented in the ESRD
population in whom the incidence of CVD death is elevated.
Around 50% of individuals with ESRD die from a CVD—a
CVD mortality rate much higher than the age-adjusted CVD
mortality rate in the general population. This discrepancy is
present across all ages, but it is most marked in the younger
age group, in which the CVD mortality rate is >300-fold
in ESRD patients compared with age-matched controls with
normal renal function [51]. By the time ESRD occurs, 40%
of patients have evidence of CHF, and 85% of those patients
have abnormal LV structure and function
The relationship between renal disease and CVD mor-
tality has also been shown to extend to patients with more
moderate degrees of renal impairment. Indeed, the majority
of patients with eGFR <60mL/min/1.73m2 die from CVD-
related causes rather than progressing to ESRD. In addition,
evidence of structural and functional cardiac abnormalities
has been demonstrated. Data about cardiac structure in
the renal insuﬃciency population has been described with
echocardiographic techniques and comparable criteria for
diagnosing LVH, detecting an LVH prevalence of 16% in
patients with CrCl of >30mL/min and 38% in those with
CrCl <30mL/min [52]. Therefore, LVH is common in
patients with renal insuﬃciency even before they progress
to dialysis, and so prevalence of LVH correlates with the
degree of renal functional deterioration. Many reports have
shown that the relationship between renal impairment and
increased CVD mortality rate extends across the spectrum of
renaldysfunctiontocoverthemildestdegreeofrenaldisease.
Furthermore, this relationship appears to be maintained
through populations with broadly diverse degrees of baseline
CV health. LVH is an independent predictor of unfavorable
prognosis in the hypertensive population, and, in the LIFE
study,itsrelationshipwithalbuminexcretionwasreportedas
being independent of age, blood pressure, diabetes mellitus,
race, serum creatinine level, or smoking [53]. The prevalence
of microalbuminuria was approximately twofold higher
in patients with hypertension and eccentric or concentric
LVH and minimally elevated in the group with concentric
LV remodelling compared with patients with normal LVInternational Journal of Nephrology 5
geometry. Although the clinical signiﬁcance of impaired
renal function and LVH in patients with hypertension is not
yet fully understood, numerous reports link renal albumin
leakage with morbidity and mortality.
TheLIFEstudyalsoshowedthatthesimplemeasurement
of UACR further reﬁnes risk stratiﬁcation by LV geometry
and that patients with LVH have an increased risk of also
having albuminuria, a situation that should be further
investigated to improve treatment and counselling. The risk
for CVD endpoints increases in a stepwise trend with higher
values for UACR in patients with diabetes. Data indicate that
albuminuria at a lower level than that usually used as a cut
point in patients with diabetes deﬁnes patients at increased
risk of CVD morbidity and mortality. UACR did not predict
the risk of myocardial infarction. Perhaps diabetes itself is
a strong predictor for CVD morbidity and mortality, partly
overlapping the inﬂuence of albuminuria as a risk factor
in the population with rather low levels of albuminuria.
Other studies suggest that albuminuria at levels below
establishedvaluesisariskfactorforCHFinpatientswithand
without diabetes, signifying that the relationship between
albuminuria and CVD risk from other populations cannot
be directly applied to nondiabetic hypertensive patients [54].
Global (all risk factors) (AU: global, meaning worldwide,
or treating all risk factors in the individual patient?) and
strict control of the sum of CVD risk factors and therapeutic
actioninordertoregressalreadyestablishedvasculardamage
must be the cornerstone of the medical strategy, because, if
not stopped, the cardiorenal continuum progresses to CKD
(proteinuria, eGFR <30mL/min/1.73m2), overt CVD, and
stroke. Interventions at this point are focused on delayed
development of CV and renal events [27]. CV events and
consequent death are dramatically reduced when UACR
is decreased and GFR decline is avoided. If renal decline
progresses to the ﬁnal stage, proteinuria will occur. In type
2 diabetes, data from the Reduction of Endpoints in NIDDM
with the Angiotensin II Antagonist Losartan (RENAAL)
trial showed that changes in albuminuria in the ﬁrst 6
months of therapy were approximately linearly related to the
degreeoflong-termrenalprotection:every50%reductionin
albuminuria in the ﬁrst 6 months was associated with a 45%
reduction in the risk for ESRD during later followup [55].
Furthermore, a secondary analysis of the Irbesartan in Dia-
betic Nephropathy Trial (IDNT) demonstrated that the risk
for renal failure was reduced during the ﬁrst year of the study
when there were increases in proteinuria [56]. Subsequently,
these two studies (IDNT and RENAAL) demonstrated that
an ARB (irbesartan or losartan) was more eﬀective than
conventionaltherapyoracalciumchannelblockerinslowing
progression of nephropathy, regardless of blood pressure
control. Moreover, secondary analyses of these two large
trials demonstrated that there was some interaction between
the eﬀect of the ARB and the levels of blood pressure that
were achieved. It can also be concluded that optimal levels of
blood pressure tended to magnify the renoprotective eﬀects
of ARB in both trials. In the large cohort of patients with
hypertension, microalbuminuria, and type 2 diabetes who
participated in the Microalbuminuria, Cardiovascular, and
Renal Outcomes–Heart Outcomes Prevention Evaluation
(MICRO-HOPE), the ACEI compared with other treatments
was more eﬀective in reducing the incidence of overt
nephropathy [57]. Furthermore, the Irbesartan in Patients
with Type 2 Diabetes and Microalbuminuria (IRMA-2)
study showed that treatment with the ARB irbesartan was
much more eﬀective than conventional therapy at both
preventing the development of clinical proteinuria and
favoring regression to normoalbuminuria in patients with
microalbuminuria and type 2 diabetes, despite similar blood
pressure control [58].
4. Global Therapeutic ApproachFocusedon
Renal Outcomes
CKD progression, that is, reduced GFR, occurs at a variable
rate, with a faster rate of decline generally noted among
patients with diabetic nephropathy due to the presence of
proteinuria. Several therapeutic options have been shown
to be eﬃcient in slowing the rate of renal function decline.
Among these therapeutic treatments are blood-pressure-
reducing drugs—preferably ACEIs and/or angiotensin II
antagonists—low-salt and low-protein diets, and lipid-
lowering drugs [59]. Unfortunately, for such treatments to
be most eﬃcacious and in agreement with the European
Society of Hypertension/European Society of Cardiology
guidelines, it is necessary to identify patients in an early
stage of disease before signiﬁcant loss of renal function
has occurred. Such identiﬁcation is simpliﬁed by estimating
GFR and measuring microalbuminuria in any patient with
h y p e r t e n s i o n .U A C Rl e v e l so fa p p r o x i m a t e l y>2mg/g or
an estimated excretion rate of 2mg/day are signiﬁcantly
associated with death from CVD, myocardial infarction,
stroke, and elevated blood pressure. As a result, reductions in
albuminuria levels during treatment translate to regression
of a number of vascular abnormalities in hypertension
and thus a decrease in risk in general. In patients with
type 2 diabetes and diabetic nephropathy, and also in
patients withnondiabetic renaldisease, data indicate that the
extentofdecreasesinalbuminuriaduringrenin-angiotensin-
aldosterone system intervention is associated with the degree
of renal protection and also the degree of reduced CVD
risk [60]. Reductions in both systolic and diastolic blood
pressure are important in reducing albuminuria levels.
Despite the ﬁrm relationship between blood pressure values
and albuminuria, ACEIs and ARBs exhibit a more marked
capacity to reduce microalbuminuria in patients with hyper-
tension compared with a number of diﬀerent therapeutic
interventions, such as calcium antagonists, beta-blockers, or
diuretics [61].
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